$121.00 - $121.00
[Ala5,β-Ala8]-Neurokinin A (4-10) is a synthetic NKA(4-10) analog containing two substitutions: Ser5 is replaced by Ala and Gly8 is replaced by β-alanine.
The peptide has been used as a selective NK2 receptor agonist in smooth-muscle and gastrointestinal pharmacology, allowing NK2-mediated responses to be distinguished from NK1- and NK3-dependent effects.
Product Information
| Product Name | [Ala5,β-Ala8]-Neurokinin A (4-10) |
| Catalog No. | AS2528 |
| CAS No. | 127633-71-0 |
| Sequence | Asp-Ala-Phe-Val-β-Ala-Leu-Met-NH2 |
| Short Sequence | DAFV-βA-LM-NH2 |
| Peptide Length | 7 residues |
| Molecular Formula | C35H56N8O9S |
| Molecular Weight | Approximately 764.9 Da |
| Key Modifications | Ser5 → Ala; Gly8 → β-Ala |
| C-Terminus | Amidated |
| Pharmacological Profile | NK2 receptor agonist |
| Purity Options | Crude to 98% |
Ala5 and β-Ala8 Dual Substitution
Two positions of the NKA(4-10) fragment are modified simultaneously. Ser5 loses its hydroxyl-containing side chain through substitution with Ala, while replacement of Gly8 with β-Ala adds an additional methylene group to the local peptide backbone.
This makes the peptide useful for examining how both side-chain polarity and backbone geometry contribute to NK2 receptor activation.
NK2-Mediated Smooth-Muscle Responses
[Ala5,β-Ala8]-NKA(4-10) has been used as an NK2-selective agonist in airway and gastrointestinal tissue preparations. In ferret trachea, it produced smooth-muscle contraction without reproducing the NK1-mediated mucus secretory response.
In rat gastric studies, the peptide also produced NK2-dependent mucosal effects. A reported half-maximal protective dose against ethanol-induced gastric damage was approximately 46 nmol/kg under the conditions of that study.
We recommend treating these tissue responses as model-specific functional data. They demonstrate useful NK2 pharmacology but are not equivalent to a recombinant receptor EC50.
Research Applications
The peptide can support NK2 receptor pharmacology, gastrointestinal smooth-muscle experiments, airway studies, tachykinin receptor differentiation and NKA structure–activity research.
Frequently Asked Questions
How does this analog differ from NKA(4-10)?
Ser5 is replaced by Ala and Gly8 is replaced by β-Ala.
Is it an NK2 receptor agonist?
Yes. It has been widely used as an NK2-selective peptide agonist in functional tissue studies.
Is this the same compound as [β-Ala8]-NKA(4-10)?
No. This analog has an additional Ser5 → Ala substitution and is chemically distinct.
Is the C-terminal methionine retained?
Yes. The peptide terminates in Met-NH2, so methionine oxidation remains relevant to stability-sensitive work.